The U.S. Food and Drug Administration (FDA) has approved Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma — a type of bladder cancer — whose disease did not worsen while receiving platinum-based chemotherapy. The decision was based on data from the ongoing JAVELIN Bladder 100 Phase 3 trial (NCT02603432). That data showed that Bavencio plus best supportive care significantly prolonged overall survival and the time patients lived without disease worsening compared…
You must be logged in to read/download the full post.
The post FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer appeared first on BioNewsFeeds.